Escitalopram adverse effects

Their most frequent adverse events (nausea, somnolence, dry mouth, increased sweating) are mainly transient and mostly mild to moderate (3). In terms of adverse effects escitalopram appears to be equivalent to citalopram. For example, in placebo-controlled trials, escitalopram produced unwanted effects typical of the SSRI class, including nausea (15%), ejaculation disorders (9%), insomnia (9%), diarrhea (8%), somnolence (7%), dry mouth (6%), and dizziness (6%). 

SSRIs ATOMOXETINE t plasma concentrations and risk of adverse effects (abdominal pain, vomiting, nausea, fatigue, irritability) Atomoxetine is a selective norepinephrine reuptake inhibitor, t plasma concentrations due to inhibition of CYP2D6 by fluoxetine and paroxetine (potent), fluvoxamine and sertraline (less potent) and escitalopram and citalopram (weak) Avoid concurrent use. The interaction is usually severe with fluoxetine and paroxetine... 

Patients treated with paroxetine or sertraline showed improvement in anxiety and avoidance symptoms and a decrease in disability. Daily doses up to 60 mg of paroxetine and 200 mg of sertraline were well tolerated, and emergent adverse effects were similar to those of depression trials (e.g., nausea, sexual dysfunction, sweating, and somnolence). The onset of effect was delayed 4 to 8 weeks, and maximum benefit was often not observed until 12 weeks or longer. Sertraline is also effective in disabled patients suffering from the marked to severe form of generalized SAD. Limited data suggest that citalopram, escitalopram, and fluvoxamine are also effective in treating SAD. Fluoxetine was not effective in SAD. ... 

Citalopram, escitalopram, paroxetine and sertraline levels are moderately increased by cimetidine but the only clinically relevant effect appears to be a slight increase in adverse effects with sertraline. 

The authors of the citalopram study say that while cimetidine certainly causes an increase in the serum levels of citalopram, the extent is only moderate and because the drug is well tolerated and there are very considerable pharmacokinetic variations between individual subjects, they consider that there is no need to reduce the citalopram dosage. This advice is most likely applicahle to escitalopram, the S-isomer of citalopram. However, the manufacturer of escitalopram suggests caution, and advises that a reduction in the dose of escitalopram may he necessary (based on monitoring of adverse effects) during concurrent treatment. ... 

In a study on the effects of maca for sexual dysfunction induced by selective serotonin reuptake inhibitors (SSRI), patients who were stable on an SSRI (patients were taking escitalopram, citalopram, sertraline, venlafexine, fluoxetine, paroxetine, duloxetine, or fluvoxamine) were orally administered 1.5 or 3 g of maca daily for 12 weeks. No adverse effects of maca, including effects on SSRI efficacy, were reported, and patients in the high dose group had a modest improvement in depression (Dording et al. 2008). 

Comparative rates of adverse effects with different antidepressants One limitation of meta-analyses is that they depend on the particular head-to-head comparisons chosen by the researchers, be they industry-based or academic-based. Multiple-treatments meta-analysis is a statistical technique that was developed to extract data from multiple randomized controlled trials to test for comparative efficacy and tolerability of agents that were not compared in individual reports. The relative efficacy and tolerability of 12 different antidepressants have been studied in a multiple-treatments meta-analysis, which showed that escitalopram, sertraline, bupropion, and citalopram were better tolerated than the other antidepressants studied The... 

Citalopram is a racemic bicyclic phthalane derivative and is a highly selective serotonin re-nptake inhibitor with minimal effects on noradrenahne and dopamine nenronal renptake. Inhibition of 5-HT re-nptake by citalopram is primarily dne to the S-enantiomer (escitalopram). Its most freqnent adverse events (nansea, somnolence, dry month, increased sweating) are mainly transient and mostly mild to moderate (1). 

Ingestion-. Nausea, vomiting, abdominal pain, diarrhea, tremor, confusion, agitation, drowsiness, insomnia, flulike syndromes, blurred vision, and in rare cases, seizures and coma. Significant cardiovascular toxicity is unusual (except with citalopram). Effects include mild hypo- or hypertension, tachycardia, and ventricular dysrhythmia. Escitalopram also has been shown to cause dermatologic, gastrointestinal, sexual, respiratory, and other miscellaneous adverse reactions. 

An isolated report describes an adverse reaction (hypertension, tachycardia, fever, auditory hallucinations and confusion) in a man when he started sertraline within a day of stopping fluoxetine. A small study found that the concurrent use of citalopram and fluvoxamine increased citalopram plasma levels with beneficial effects and the manufacturers of escitalopram predict that it may be similarly affected. 

Acneiform eruption SSRls are recognised to be associated with a wide range of cutaneous side effects. Although acneiform eruption is listed as an infrequent side effect of escitalopram, reports have been rare, with none in the English-language literature. In particular, neither acneiform eruptions nor any serious adverse cutaneous reactions have been reported with its use in of children and adolescents. A case of acneiform eruption in a young adult was reported [40 ]. 

---